NCT02287233 - A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions

Acute Myelogenous LeukemiaAML

Interventions

DRUG

Venetoclax

Venetoclax will be taken orally once daily.

DRUG

Cytarabine

Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.

Trial Locations (9)

Calvary Mater Newcastle /ID# 136076, Waratah

Alfred Health /ID# 131180, Melbourne

Weill Cornell Medical College /ID# 131170, New York

University of Pittsburgh MC /ID# 131168, Pittsburgh

Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 133979, Hamburg

Duplicate_A.O.U. Policlinico S.Orsola-Malpighi /ID# 131183, Bologna

Univ Kansas Med Ctr /ID# 131175, Kansas City

Vanderbilt University Medical Center /ID# 131177, Nashville

Fred Hutchinson Cancer Research Center /ID# 131178, Seattle